Fully biologically active when compared to standard. The ED50 determined by a chemotaxis bioassay using human peripheral blood lymphocytes is less than 200 ng/ml, corresponding to a specific activity of >, 5.0 × 103 IU/mg.
Pureté
> 97 % by SDS-PAGE and HPLC analyses.
niveau d'endotoxine
Level Less than 1EU/µg of rMuExodus-2/CCL21 as determined by LAL method
CCL21
Origine: Souris
Hôte: Escherichia coli (E. coli)
Recombinant
> 95 %
WB, SDS, Imm, PC
Restrictions
For Research Use only
Format
Lyophilized
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at < -20 °C. Further dilutions should be made in appropriate buffered solutions.
Exodus-2/CCL21 is a novel CC chemokine discovered independently by three groups from the EST database, and shows 21-33% identity to other CC chemokines. Exodus-2 contains the four conserved cysteines characteristic of beta chemokines plus two additional cysteines in its unusually long carboxylterminal domain. It is expressed in lymph nodes of certain endothelial cells, and in the spleen and appendix. Exodus-2 chemoattracts T and B lymphocytes and inhibits hematopoiesis. Synonym: Exodus-2/CCL21, Mouse. Formulation: Lyophilized from a 0.2µm filtered concentrated solution in 20mM PB, pH 7.4, 150mM NaCl.
Poids moléculaire
12.0 kDa, a single, non-glycosylated polypeptide chain containing 110 amino acids.